HHS’s October 28, 2026 policy covers six unapproved peptides, according to Pink Sheet, and it lets pharmacies compound them without fear of federal enforcement. The six an FDA advisory panel backed in July were BPC-157, KPV, TB-500, MOTS-c, epitalon and semax, according to Drug Discovery News. Check the HHS policy text to confirm it lists the same six. That is a permission about pharmacy compounding, not FDA approval of any of them as a drug, and FDA’s own scientific reviewers had advised against adding them.
What are the six unapproved peptides HHS will allow?
The six are the ones an FDA advisory panel backed in July, in votes Drug Discovery News describes as closely split. The panel recommended adding them to the FDA’s 503A bulk compounding list. The six named below are the ones the panel backed, so check the HHS policy text itself to confirm it lists the same six.
| Peptide | What the FDA’s bulk-substances page says (as of October 2026) |
|---|---|
| BPC-157 | FDA has identified no, or only limited, safety-related information for the proposed routes of administration. |
| KPV | FDA has not identified any human exposure data for KPV by any route. |
| TB-500 (thymosin beta-4 fragment LKKTETQ) | FDA has not identified any human exposure data and lacks important information on its safety. |
| MOTS-c | FDA has not identified any human exposure data and lacks important information on its safety. |
| Epitalon | FDA has not identified safety-related information for the proposed route of administration. |
| Semax (heptapeptide) | FDA has no, or limited, safety-related information for the proposed routes of administration. |
Drug Discovery News says the uses the panel discussed ranged from wound healing to insomnia. The FDA’s full page is at FDA’s list of bulk substances with significant safety risks. For semax specifically, our Semax peptide guide covers price, safety and FDA status.
Why do the numbers 19, 14, 7 and 6 keep getting mixed up?
Each number comes from a different step in the story.
- 19: Johns Hopkins says that a few years ago the FDA decided 19 peptides were unsafe and put them on a list that explicitly prohibits compounding. OpenLoop Health says the FDA moved those 19 from Category 1 to Category 2 in late 2023.
- 14: On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. said on The Joe Rogan Experience that he wanted to move 14 of the 19 back to Category 1, which would let traditional pharmacies compound them, according to OpenLoop Health (updated March 13, 2026). OpenLoop says an official FDA list of those 14 had not been published. Its own list of twelve names, which it calls industry-informed predictions only, is AOD-9604, BPC-157, emideltide, epitalon, GHK-Cu, kisspeptin-10, KPV, MOTS-C, semax, selank, TB-500 and thymosin alpha-1.
- 7: In July, the FDA advisory committee looked at seven selected peptides, according to Johns Hopkins’s explainer on FDA peptide rules. Drug Discovery News reports it backed six and rejected emideltide, for opioid withdrawal and sleep disorders.
- 6: The six the panel backed. Pink Sheet says HHS’s October 28 policy covers six peptides, and you should check its text to confirm it names the same six.
Most of the “banned” talk refers to Category 2. OpenLoop Health describes Category 2 as bulk substances identified as presenting significant safety risks that cannot be used in compounding unless the FDA authorizes their use through rulemaking. That article is dated March 13, 2026.
Which peptides are FDA-approved, and which are not?
Johns Hopkins explains that insulin and GLP-1 drugs are peptides approved by the FDA after studies demonstrate safety and effectiveness. Other peptides have limited evidence to support their use and are not approved by the FDA, and that includes the six above. For a current list of approved drugs, check the FDA directly rather than a list copied from a seller or blog.
Which peptides are now legal, and what changed on October 28?
Pink Sheet’s report says HHS, not the FDA, issued an enforcement discretion policy on Oct. 28, and that it lets pharmacies compound six peptides without fear of federal enforcement. Pink Sheet also says the policy presents the FDA’s safety concerns as hypothetical, even though one FDA review cited animal safety signals.
So the answer to “which are legal” is narrow. Under this policy, pharmacies can compound six peptides without federal enforcement, according to Pink Sheet. Johns Hopkins draws the line clearly: the Federal Food, Drug, and Cosmetic Act does allow the FDA to permit them to be sold, “but that is not the same as a determination of their safety and effectiveness.”
What is still unknown: as of October 2026, the decision on a formal rule sits with the FDA. Drug Discovery News says that rulemaking step could take a year or more. Johns Hopkins says whether it needs an additional regulatory process “is yet to be seen,” and that without other steps, oversight “would have to be handled at the state level.”
Is it legal to buy peptides online?
Johns Hopkins says many of these unapproved peptides are being sold illegally online. Some sellers label packages “For Research Use Only,” and Johns Hopkins says that label does not get them out of the legal requirement. The HHS policy covers pharmacy compounding, which is a different route from research-labeled products sold online, so the October 28 headlines are not permission to buy from a website.
What are the side effects and safety concerns?
For most of the six, the FDA’s page says it has no, or only limited, safety information, or no human exposure data. The same page lists serious events for several other peptides:
- Ipamorelin (not one of the six): a study identified serious adverse events, including death, when it was given intravenously for improving gastric motility.
- CJC-1295 (not one of the six): serious adverse events including increased heart rate and a systemic vasodilatory reaction.
- Melanotan II (not one of the six): published case reports of serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.
- AOD-9604 (not one of the six): serious adverse events identified, though causality is not clear.
- Cathelicidin LL-37 (not one of the six): nonclinical findings suggest detrimental effects on male reproduction and that it can be protumorigenic in some tissues.
Johns Hopkins notes that the safety framework for dietary supplements, including adverse-event reporting and facility inspections, does not exist for peptides. For what studies have reported about side effects, see peptides side effects in studies (our research library).
Johns Hopkins’s commentary advises against going to a medical professional connected to a website selling unapproved peptides. Talk with a trusted clinician about evidence-backed options first.
Are peptides anti-aging?
Anti-aging is one of the benefits people attach to peptides. Johns Hopkins says peptides with limited evidence have champions who make claims ranging from muscle growth to infection. Its view is that the question should be settled by studies: “the idea is to know which peptides work and are safe so that people can make decisions based on good information.” To see what trials have found, read what peptides trials found (our research library).
What are your options, side by side?
| Option | What it is | What the sources show | Who it suits | Limits and cost |
|---|---|---|---|---|
| Approved peptide drugs | Insulin and GLP-1 drugs | Approved by the FDA after studies demonstrate safety and effectiveness (Johns Hopkins) | People a clinician prescribes them for | Cost is set by the prescriber and pharmacy; check directly. |
| Clinical studies | Studies of investigational peptides, listed at ClinicalTrials.gov | NIDDK says federally funded studies can be filtered there | People who qualify for a specific study | NIH does not review the industry, university and individual studies on that list and cannot ensure they are safe for you (NIDDK). Check the study listing for any cost. |
| Compounded peptides, the six the panel backed | Pharmacy compounding, which Pink Sheet reports HHS’s October 28 policy allows for six peptides | FDA’s page says it has no, or only limited, safety information for most of the six | People who discuss it with a clinician | Not FDA approved. Prices change; check with the pharmacy. |
| Research-labeled peptides sold online | Sold as “For Research Use Only” | Johns Hopkins says many are sold illegally online, and the label does not remove the legal requirement | Johns Hopkins’s commentary calls taking unproven products “not a good idea” | No pre-market review, adverse-event reporting or facility inspection framework, per Johns Hopkins |
| Erectile dysfunction treatments, if that is your concern | Oral PDE5 inhibitors, testosterone, injectable medicines, vacuum devices, surgery | NIDDK lists these as options a health care professional may discuss | Men with erection problems | Talk with your health care professional first; NIDDK warns about erections lasting longer than 4 hours (priapism). |
None of these is the right choice for everyone. Your clinician can help you compare them against your history.
Joe Rogan and celebrity peptide use
The Rogan link in this story is RFK Jr.’s February 27, 2026 interview on The Joe Rogan Experience, where he talked about making peptides more accessible, according to OpenLoop Health. That was a policy discussion. It is not a report of what Rogan uses. Stories about celebrities injecting peptides are personal accounts, not studies. If a person has spoken about their own use on the record, that is their account, and a famous person’s routine is not evidence about a peptide’s safety for you.
If erection problems are what brought you here
If erections are the concern, our main cause of erectile dysfunction guide covers the causes. NIDDK says health care professionals often start with lifestyle changes: quitting smoking, limiting alcohol, increasing physical activity, keeping a healthy weight and following a healthy eating plan. Its treatment list covers oral PDE5 inhibitors, testosterone, injectable medicines and suppositories, vacuum devices and surgery, and notes that most people with ED do not need surgery. NIDDK adds: “Do not stop taking any medicines on your own.”
Before you decide
- Check the final six names in the HHS policy text, and check each peptide’s entry on the FDA’s bulk-substances page.
- Ask a clinician whether an approved option or a clinical study fits your situation, and tell them about every medicine you take.
- If a pharmacy route comes up, ask whether the peptide is one of the six and ask the pharmacy for its current price. Prices change, so check today’s price directly.
- Watch for the FDA’s next step. OpenLoop Health points readers to the Federal Register for formal federal updates.
By HealthDataConsortium.org Research Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.
